Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Myeloma

Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma

Leukemia volume 20, pages 2034–2040 (2006)Cite this article

Abstract

A specific role for increased level of expression of CKS1B, as a consequence of chromosome 1q21 copy number gain, has been postulated as both pathogenic, as well as a powerful clinical prognostic factor in multiple myeloma (MM). The purpose of this study is to determine the clinical associations and prognostic impact of copy number gain at chromosome 1q21 (with a bacteria artificial chromosome clone containing CKS1B) and CKS1B gene level of expression in MM. We studied the chromosome region 1q21 for copy number change in a cohort of myeloma patients treated by high-dose therapy with stem-cell rescue (HDT) (n=159). A separate cohort of patients, treated by HDT was studied for CKS1B messenger RNA expression by gene expression profiling (n=67). 1q21 gain was then correlated with clinical parameters and survival. Gain of 1q21 copy number was detected in about a third of MM and was associated with more proliferative disease and poor-risk cytogenetic categories such as t(4;14), and chromosome 13 deletion. Both 1q21 gain and increase gene expression level were significantly associated with reduced survival. However, neither is an independent prognostic marker in MM on multivariate Cox proportional hazard analysis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

Accession codes

Accessions

GenBank/EMBL/DDBJ

References

  1. Fonseca R, Barlogie B, Bataille R, Bastard C, Bergsagel PL, Chesi M et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004; 64: 1546–1558.

    Article  CAS  Google Scholar 

  2. Fonseca R, Debes-Marun CS, Picken EB, Dewald GW, Bryant SC, Winkler JM et al. The recurrent IgH translocations are highly associated with nonhyperdiploid variant multiple myeloma. Blood 2003; 102: 2562–2567.

    Article  CAS  Google Scholar 

  3. Smadja NV, Leroux D, Soulier J, Dumont S, Arnould C, Taviaux S et al. Further cytogenetic characterization of multiple myeloma confirms that 14q32 translocations are a very rare event in hyperdiploid cases. Genes Chromosomes Cancer 2003; 38: 234–239.

    Article  Google Scholar 

  4. Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy Jr J . Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106: 296–303.

    Article  CAS  Google Scholar 

  5. Mattioli M, Agnelli L, Fabris S, Baldini L, Morabito F, Bicciato S et al. Gene expression profiling of plasma cell dyscrasias reveals molecular patterns associated with distinct IGH translocations in multiple myeloma. Oncogene 2005; 24: 2461–2473.

    Article  CAS  Google Scholar 

  6. Chng WJ, Van Wier SA, Ahmann GJ, Winkler JM, Jalal SM, Bergsagel PL et al. A validated FISH trisomy index demonstrates the hyperdiploid and nonhyperdiploid dichotomy in MGUS. Blood 2005; 106: 2156–2161.

    Article  CAS  Google Scholar 

  7. Fonseca R, Bailey RJ, Ahmann GJ, Rajkumar SV, Hoyer JD, Lust JA et al. Genomic abnormalities in monoclonal gammopathy of undetermined significance. Blood 2002; 100: 1417–1424.

    CAS  PubMed  Google Scholar 

  8. Kaufmann H, Ackermann J, Baldia C, Nosslinger T, Wieser R, Seidl S et al. Both IGH translocations and chromosome 13q deletions are early events in monoclonal gammopathy of undetermined significance and do not evolve during transition to multiple myeloma. Leukemia 2004; 18: 1879–1882.

    Article  CAS  Google Scholar 

  9. Shaughnessy J . Amplification and overexpression of CKS1B at chromosome band 1q21 is associated with reduced levels of p27Kip1 and an aggressive clinical course in multiple myeloma. Hematology 2005; 10 (Suppl 1): 117–126.

    Article  CAS  Google Scholar 

  10. Shaughnessy Jr JD, Barlogie B . Using genomics to identify high-risk myeloma after autologous stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 77–80.

    Article  CAS  Google Scholar 

  11. Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M et al. The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 2001; 3: 321–324.

    Article  CAS  Google Scholar 

  12. Spruck C, Strohmaier H, Watson M, Smith AP, Ryan A, Krek TW et al. A CDK-independent function of mammalian Cks1: targeting of SCF(Skp2) to the CDK inhibitor p27Kip1. Mol Cell 2001; 7: 639–650.

    Article  CAS  Google Scholar 

  13. Hanamura I, Stewart JP, Huang Y, Zhan F, Santra M, Sawyer JR et al. Frequent gain of chromosome band 1q21 in plasma cell dyscrasias detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem cell transplantation. Blood, (E-pub ahead of print 16 May 2006) 2006, (DOI 10.1182/blood-2006-03-009910).

  14. Avet-Loiseau H, Andree-Ashley LE, Moore 2nd D, Mellerin MP, Feusner J, Bataille R et al. Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes Chromosomes Cancer 1997; 19: 124–133.

    Article  CAS  Google Scholar 

  15. Gutierrez NC, Hernandez JM, Garcia JL, Canizo MC, Gonzalez M, Hernandez J et al. Differences in genetic changes between multiple myeloma and plasma cell leukemia demonstrated by comparative genomic hybridization. Leukemia 2001; 15: 840–845.

    Article  CAS  Google Scholar 

  16. Cigudosa JC, Rao PH, Calasanz MJ, Odero MD, Michaeli J, Jhanwar SC et al. Characterization of nonrandom chromosomal gains and losses in multiple myeloma by comparative genomic hybridization. Blood 1998; 91: 3007–3010.

    CAS  PubMed  Google Scholar 

  17. Sawyer JR, Lukacs JL, Munshi N, Desikan KR, Singhal S, Mehta J et al. Identification of new nonrandom translocations in multiple myeloma with multicolor spectral karyotyping. Blood 1998; 92: 4269–4278.

    CAS  Google Scholar 

  18. Sawyer JR, Tricot G, Lukacs JL, Binz RL, Tian E, Barlogie B et al. Genomic instability in multiple myeloma: evidence for jumping segmental duplications of chromosome arm 1q. Genes Chromosomes Cancer 2005; 42: 95–106.

    Article  CAS  Google Scholar 

  19. Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S et al. The molecular classification of multiple myeloma. Blood, (E-pub ahead of print 25 May 2006) 2006, (DOI 10.1182/blood-2005-11-013458).

  20. Ahmann GJ, Jalal SM, Juneau AL, Christensen ER, Hanson CA, Dewald GW et al. A novel three-color, clone-specific fluorescence in situ hybridization procedure for monoclonal gammopathies. Cancer Genet Cytogenet 1998; 101: 7–11.

    Article  CAS  Google Scholar 

  21. Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA et al. Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood 2003; 101: 4569–4575.

    Article  CAS  Google Scholar 

  22. Perez EA, Roche PC, Jenkins RB, Reynolds CA, Halling KC, Ingle JN et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002; 77: 148–154.

    Article  Google Scholar 

  23. Abraham RS, Ballman KV, Dispenzieri A, Grill DE, Manske MK, Price-Troska TL et al. Functional gene expression analysis of clonal plasma cells identifies a unique molecular profile for light chain amyloidosis. Blood 2005; 105: 794–803.

    Article  CAS  Google Scholar 

  24. Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA . Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993; 81: 3382–3387.

    CAS  PubMed  Google Scholar 

  25. Gutierrez NC, Garcia JL, Hernandez JM, Lumbreras E, Castellanos M, Rasillo A et al. Prognostic and biologic significance of chromosomal imbalances assessed by comparative genomic hybridization in multiple myeloma. Blood 2004; 104: 2661–2666.

    Article  CAS  Google Scholar 

  26. Liebisch P, Wendl C, Wellmann A, Krober A, Schilling G, Goldschmidt H et al. High incidence of trisomies 1q, 9q, and 11q in multiple myeloma: results from a comprehensive molecular cytogenetic analysis. Leukemia 2003; 17: 2535–2537.

    Article  CAS  Google Scholar 

  27. Rosinol L, Carrio A, Blade J, Queralt R, Aymerich M, Cibeira MT et al. Comparative genomic hybridisation identifies two variants of smoldering multiple myeloma. Br J Haematol 2005; 130: 729–732.

    Article  CAS  Google Scholar 

  28. Chen W, Palanisamy N, Schmidt H, Teruya-Feldstein J, Jhanwar SC, Zelenetz AD et al. Deregulation of FCGR2B expression by 1q21 rearrangements in follicular lymphomas. Oncogene 2001; 20: 7686–7693.

    Article  CAS  Google Scholar 

  29. Cheng KW, Lahad JP, Kuo WL, Lapuk A, Yamada K, Auersperg N et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004; 10: 1251–1256.

    Article  CAS  Google Scholar 

  30. Craig RW, Jabs EW, Zhou P, Kozopas KM, Hawkins AL, Rochelle JM et al. Human and mouse chromosomal mapping of the myeloid cell leukemia-1 gene: MCL1 maps to human chromosome 1q21, a region that is frequently altered in preneoplastic and neoplastic disease. Genomics 1994; 23: 457–463.

    Article  CAS  Google Scholar 

  31. Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, Houldsworth J et al. MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 2000; 95: 2666–2671.

    CAS  PubMed  Google Scholar 

  32. Gilles F, Goy A, Remache Y, Shue P, Zelenetz AD . MUC1 dysregulation as the consequence of a t(1;14)(q21;q32) translocation in an extranodal lymphoma. Blood 2000; 95: 2930–2936.

    CAS  PubMed  Google Scholar 

  33. Hatakeyama S, Osawa M, Omine M, Ishikawa F . JTB: a novel membrane protein gene at 1q21 rearranged in a jumping translocation. Oncogene 1999; 18: 2085–2090.

    Article  CAS  Google Scholar 

  34. Hatzivassiliou G, Miller I, Takizawa J, Palanisamy N, Rao PH, Iida S et al. IRTA1 and IRTA2, novel immunoglobulin superfamily receptors expressed in B cells and involved in chromosome 1q21 abnormalities in B cell malignancy. Immunity 2001; 14: 277–289.

    Article  CAS  Google Scholar 

  35. Inoue J, Otsuki T, Hirasawa A, Imoto I, Matsuo Y, Shimizu S et al. Overexpression of PDZK1 within the 1q12-q22 amplicon is likely to be associated with drug-resistance phenotype in multiple myeloma. Am J Pathol 2004; 165: 71–81.

    Article  CAS  Google Scholar 

  36. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM et al. Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 1998; 91: 1873–1881.

    CAS  Google Scholar 

  37. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B et al. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell 2006; 9: 313–325.

    Article  CAS  Google Scholar 

  38. Sawyer JR, Tricot G, Mattox S, Jagannath S, Barlogie B . Jumping translocations of chromosome 1q in multiple myeloma: evidence for a mechanism involving decondensation of pericentromeric heterochromatin. Blood 1998; 91: 1732–1741.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

RF is a Clinical Investigator of the Damon Runyon Cancer Research Fund. This work was supported by the International Waldenström Macroglobulinemia Foundation, and Grants R01 CA83724-01, SPORE P50 CA100707-01, the Donaldson Charitable Trust fund and P01 CA62242 from the National Cancer Institute, and the Fund to Cure Myeloma. WJC is funded by an International Fellowship from the Agency for Science, Technology and Research, Singapore (A*STAR).

Author information

Authors and Affiliations

  1. Division of Hematology and Oncology, Mayo Clinic Comprehensive Cancer Center, Scottsdale, AZ, USA

    R Fonseca, S A Van Wier, W J Chng, P L Bergsagel & G J Ahmann

  2. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA

    R Ketterling

  3. Division of Hematology, Mayo Clinic, Rochester, MN, USA

    M Q Lacy, A Dispenzieri, S V Rajkumar, P R Greipp, M R Litzow, T Price-Troska, K J Henderson & M A Gertz

Authors
  1. R Fonseca
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S A Van Wier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W J Chng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Ketterling
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Q Lacy
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. A Dispenzieri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. P L Bergsagel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. S V Rajkumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. P R Greipp
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M R Litzow
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. T Price-Troska
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. K J Henderson
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. G J Ahmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M A Gertz
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to R Fonseca.

Additional information

Supplementary Information accompanies the paper on the Leukemia website (http://www.nature.com/leu)

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fonseca, R., Van Wier, S., Chng, W. et al. Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma. Leukemia 20, 2034–2040 (2006). https://doi.org/10.1038/sj.leu.2404403

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404403

Keywords

This article is cited by

Search

Advanced search

Quick links